January 19, 2022
Psychedelic profiles Ketamine In 2021 the psychedelic healthcare market was worth US$190 million, dominated by ketamine-assisted therapy. Distinct from other
January 11, 2022
Psilocybin-assisted therapy for major depressive disorder and treatment-resistant depression are in Phase II trials, and may be approved by the
January 5, 2022
Last year MAPS completed its Phase IIIa trials with MDMA in the treatment of PTSD. The subsequent data release grabbed
December 29, 2021
2021 was a seminal year for psychedelic medicine, with data released from groundbreaking clinical trials harnessing MDMA and psilocybin. The
December 21, 2021
To alter public perception and promote the acceptance of psychedelics as medicines, Gwella launched Mojo – a functional mushroom product
December 15, 2021
For psychedelic medicines to reach as many patients as possible, developers need to secure buy-in at every level of the
December 8, 2021
Awakn Life Sciences recently signed a memorandum of understanding with Devon Partnership NHS Trust and the University of Exeter, to
December 1, 2021
In 2021, psychedelic medicines moved from the frontiers of scientific research to the front pages of newspapers worldwide. This was
November 23, 2021
To strengthen the adoption of psychedelic-assisted therapies, drug developers are striving to minimise their cost – with shorter lasting tryptamines.
November 17, 2021
Member of Parliament Crispin Blunt has championed the campaign to reschedule psilocybin for scientific and research purposes in the UK.
November 10, 2021
This week COMPASS Pathways provided an eagerly anticipated update from its Phase IIb clinical trial. The largest ever study with
November 3, 2021
Cybin became the first psychedelic healthcare company to list on the New York Stock Exchange, with its psilocybin formulation to
